Clinical trial NCT06899204: Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Official title: A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atopic Dermatitis
Atopic Dermatitis, Unspecified
Dermatitis, Atopic
Keywords: Real world efficacy
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2025-03-27
Enrollment: 150
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population eligible for enrollment includes adult and adolescent patients aged ≥12 years diagnosed with moderate to severe AD who receive at least one dose of abrocitinib.

Brief summary: This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States.

The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.


Eligibility criteria: This NI study will enroll 150 patients from approximately 15 sites across the US. The study population eligible for enrollment includes adult and adolescent patients aged ≥12 years diagnosed with moderate to severe AD who receive at least one dose of abrocitinib and satisfy the inclusion and exclusion criteria. Patients who had inadequate response or intolerance to previous ≤2 biologic therapies will be included in this study as there is a lack of effectiveness data for abrocitinib in these patients. As this will be an observational study, there will be no sampling and all patients that meet the inclusion and exclusion criteria will be recruited consequently. The study will be open for enrollment for approximately 12 months after the first patient has been enrolled. Regarding the inclusion and exclusion criteria, in the real-world setting recruitment may be slower than expected, thus depending on the observed enrollment rate, the enrollment period and number of sites may be reassessed and revised during the study.

9.2.1. Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Participants who have chronic AD that has been present for ≥1 year before screening.
2. Male and female patients aged \>12 years at baseline.
3. Patients with diagnosis of moderate-to-severe atopic dermatitis confirmed by a certified dermatologist, who are prescribed abrocitinib for use in accordance with the product label (USPI) and independently of the decision to enroll the patient in this study
4. Patients who have inadequate responses or are intolerant to ≤2 previous biologic therapy approved for M2S AD. (Patients shall have had an inadequate response and/or intolerance to at least one, but no more than 2 biologic therapies approved for moderate-to-severe AD)
5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Following receipt of oral and written information about the study, the adolescent (depending on local institutional review board/independent ethics committee requirements) must provide assent, and one or both (according to local regulations) parents or guardians of the child must provide signed informed consent before any study-related activity is carried out.
6. Patients, who in the opinion of the investigator, are willing and able to comply with regular clinic visits as per standard practice at the site and agree to complete PRO questionnaires and other patient completed questions.

9.2.2. Exclusion Criteria

Patients meeting any of the following criteria will not be included in the study:

1. Patients, that currently have active forms of other inflammatory skin diseases, other than AD or have evidence of skin conditions (eg, psoriasis, seborrheic dermatitis, Lupus) at the time of Day 1 that would interfere with evaluation of atopic dermatitis or response to treatment.
2. Patients previously treated with abrocitinib or other oral/systemic JAK inhibitors
3. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.
4. Patient eligibility should be reviewed, documented, and confirmed by an appropriately qualified member of the investigator's study team before patients are enrolled in the study.

Primary outcomes:
measure: Percentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date
timeFrame: Baseline, week 16
measure: Percentage of patients achieving ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS) collected daily all through the study from baseline at Week 2 by e-diary assessment
timeFrame: Baseline, week 2
Secondary outcomes:
measure: Percentage of patients achieving EASI-75, 90 and 100 from baseline at Week 4 and 16 after index date
timeFrame: Baseline, week 4, week 16
measure: Percentage of patients achieving v-IGA response of Clear (0) or Almost Clear (1) and ≥ 2 points improvement from baseline at Week 4 and 16 after index date
timeFrame: Baseline, week 4, week 16
measure: Change from baseline in total percentage of BSA at week 4 and 16
timeFrame: Baseline, week 4, week 16
measure: Percentage of patients achieving Peak Pruritus Numerical Rating Scale (PP-NRS) of 0 or 1 collected daily all through the study at Wk 4, 12 and 16
timeFrame: Baseline, week 4, 12 and 16
measure: Percentage of patients achieving PP-NRS-4 at week 2, 4, 12 and 16 from baseline.
timeFrame: Baseline, week 2, 4, 12 and 16
measure: Absolute change from baseline in PP-NRS score at week 2
timeFrame: Baseline, week2
measure: Proportion of patients overall "Very Satisfied" and "Satisfied" with abrocitinib at Wk 4, 12 and 16 with TSQM-9
timeFrame: Baseline, week 4, 12 and 16
measure: Percentage of patients that report symptoms to be "minimal" or "absent" on the patient global impression of severity at week 4, 12 and 16
timeFrame: Baseline week 4, 12 and 16
measure: Change from baseline in Medical Outcomes Study - Sleep Scale (MOS-Sleep Scale) at Wk 4, 12 and 16
timeFrame: Baseline, week 4, 12 and 16
measure: Percentage of Participants with an ADCT Total Score Reduction ≥ 5 from baseline at week 4, 12 and 16
timeFrame: Baseline, week 4, 12 and 16
measure: Percentage of Participants Achieving Improvement (reduction) in DLQI/CDLQI of ≥ 4 points vs baseline at week 4, 12 and 16
timeFrame: Baseline week 4, 12 and 16
measure: Observational change in pigment alteration from baseline at week 4 and 16 by visual assessment of available photography
timeFrame: Baseline, week 4, and 16
measure: Cilinical Characteristics: Type of prior AD treatment at specific medication level and Route of Administration
timeFrame: Baseline
measure: Demographic charasteristics: Number/percentage of patients by age, sex, race, ethnicity, socioeconomic status, state of residence
timeFrame: Baseline
measure: Clinical Characteristics: Number/percentage of patients by smoking status, medical history
timeFrame: Baseline
measure: Clinical Characteristics: Duration of prior therapy/frequency
timeFrame: Baseline
measure: Clinical Characteristics: Total number of AD treatments used prior to abrocitinib initiation
timeFrame: Baseline
measure: Clinical characteristics : Reason for switching to abrocitinib from previous biologic
timeFrame: Baseline
measure: Outcome: Assessment of efficacy in patients who received a dose change after baseline visit (dose increase or decrease)
timeFrame: Week 4, week 16
measure: Assess early improvement in itch (within min/hrs) after first dose
timeFrame: Baseline, day 1 after index date
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: